France’s drug authority announced on Thursday that it will suspend the use of two diabetes drugs, Actos and Competact, over concerns regarding cancer risks. The decision to issue the order for drug suspension came after the results of an official study conducted by the French Public Health Insurance Office revealed that the treatments were found [...]
